ScholarMate
English简体中文繁體中文
客服热线:400-1616-289
登录注册
期刊论文

Proposed clinical phases for the improvement of personalized treatment of checkpoint inhibitor-related pneumonitis

Zhou, Chengzhi; Yang, Yilin; Lin, Xinqing; Fang, Nianxin; Chen, Likun; Jiang, Juhong; Deng, Haiyi; Deng, Yu; Wan, Minghui; Qiu, Guihuan; Sun, Ni; Wu, Di; Long, Xiang; Zhong, Changhao; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Ouyang, Ming; Qin, Yinyin; Petrella, Francesco; Fiorelli, Alfonso; Bravaccini, Sara; Kataoka, Yuki; Watanabe, Satoshi; Goto, Taichiro; Solli, Piergiorgio; Igai, Hitoshi; Saito, Yuichi; Tsoukalas, Nikolaos; Nakada, Takeo; Li, Shiyue*; Chen, Rongchang*广州医学院; 北京大学; 南方医科大学; 中山大学; 1; 东莞市人民医院
Frontiers in Immunology2022-7-20DOI: 10.3389/fimmu.2022.935779
6被引11阅读
引用收藏
分享

摘要

Background: Checkpoint inhibitor-related pneumonitis (CIP) is a lethal immune-related adverse event. However, the development process of CIP, which may provide insight into more effective management, has not been extensively examined. @@@ Methods: We conducted a multicenter retrospective analysis of 56 patients who developed CIP. Clinical characteristics, radiological features, histologic features, and laboratory tests were analyzed. After a comprehensive analysis, we proposed acute, subacute, and chronic phases of CIP and summarized each phase's characteristics. @@@ Results: There were 51 patients in the acute phase, 22 in the subacute phase, and 11 in the chronic phase. The median interval time from the beginning of CIP to the different phases was calculated (acute phase: <= 4.9 weeks; subacute phase: 4.9 similar to 13.1 weeks; and chronic phase: >= 13.1 weeks). The symptoms relieved from the acute phase to the chronic phase, and the OP grade and Performance Status score decreased (P<0.05). The main change in radiologic features was the absorption of the lesions, and 3 (3/11) patients in the chronic phase had persistent traction bronchiectasis. For histologic features, most patients had acute fibrinous pneumonitis in the acute phase (5/8), and most had organizing pneumonia in the subacute phase (5/6). Other histologic changes advanced over time, with the lesions entering a state of fibrosis. Moreover, the levels of interleukin-6, interleukin-10 and high-sensitivity C-reactive protein (hsCRP) increased in the acute phase and decreased as CIP progressed (IL-6: 17.9 vs. 9.8 vs. 5.7, P=0.018; IL-10: 4.6 vs 3.0 vs. 2.0, P=0.041; hsCRP: 88.2 vs. 19.4 vs. 14.4, P=0.005). @@@ Conclusions: The general development process of CIP can be divided into acute, subacute, and chronic phases, upon which a better management strategy might be based devised.

学科与关键词

关键词
immune checkpoint inhibitorcheckpoint inhibitor-related pneumonitisclinical phasesmanagementglucocorticoids
相关
加载中…
  • Clinical types of checkpoint inhibitor-related pneumonitis in lung cancer patients: a multicenter experience
    Lin, Xinqing; Deng, Haiyi; Chen, Likun; Wu, Di; Chen, Xiaobo; Yang, Yilin; Chen, Tao; Xie, Xiaohong; Xie, Zhanhong; Liu, Ming; Ouyang, Ming; Qin, Yinyin; Li, Shiyue; Zhong, Nanshan; Gregg, Jeffrey P.; Horita, Nobuyuki; Song, Yong*; Zhou, Chengzhi*Translational Lung Cancer Research, 2021, 10(1): 415-429.被引 12
  • Comprehensive Analysis of the Immune Microenvironment in Checkpoint Inhibitor Pneumonitis
    Lin, Xinqing; Deng, Jiaxi; Deng, Haiyi; Yang, Yilin; Sun, Ni; Zhou, Maolin; Qin, Yinyin; Xie, Xiaohong; Li, Shiyue; Zhong, Nanshan; Song, Yong*; Zhou, Chengzhi*Frontiers in Immunology, 2022, 12: 818492.被引 13
  • Risk Factors for Refractory Immune Checkpoint Inhibitor-related Pneumonitis in Patients With Lung Cancer
    Tan, Peixin; Huang, Wei; He, Xinyan; Lv, Fengquan; Cui, Yanhai*; Du, Shasha*Journal of Immunotherapy, 2023, 46(2): 64-73.被引 3
查看全部 →

发表信息

论文状态
公开发表
期刊
Frontiers in Immunology
发表日期
2022-07-20
卷期
第 13 卷
页码
935779
DOI
10.3389/fimmu.2022.935779
语言
ENGLISH
期刊等级
2区
成果收录
SCIE

作者

  • Z

    Zhou, Chengzhi (第一作者)

    1 · guangzhou med univ

  • Y

    Yang, Yilin

    1 · guangzhou med univ

查看全部 32 位作者收起作者
  • L

    Lin, Xinqing

    1 · guangzhou med univ

  • F

    Fang, Nianxin

    dongguan peoples hosp · southern med univ

  • C

    Chen, Likun

    sun yat sen univ

  • J

    Jiang, Juhong

    1 · guangzhou med univ

  • D

    Deng, Haiyi

    1 · guangzhou med univ

  • D

    Deng, Yu

    1 · guangzhou med univ

  • W

    Wan, Minghui

    1 · guangzhou med univ

  • Q

    Qiu, Guihuan

    1 · guangzhou med univ

  • S

    Sun, Ni

    1 · guangzhou med univ

  • W

    Wu, Di

    1 · 2

  • L

    Long, Xiang

    peking univ

  • Z

    Zhong, Changhao

    1 · guangzhou med univ

  • X

    Xie, Xiaohong

    1 · guangzhou med univ

  • X

    Xie, Zhanhong

    1 · guangzhou med univ

  • L

    Liu, Ming

    1 · guangzhou med univ

  • O

    Ouyang, Ming

    1 · guangzhou med univ

  • Q

    Qin, Yinyin

    1 · guangzhou med univ

  • P

    Petrella, Francesco

  • F

    Fiorelli, Alfonso

  • B

    Bravaccini, Sara

  • K

    Kataoka, Yuki

  • W

    Watanabe, Satoshi

  • G

    Goto, Taichiro

  • S

    Solli, Piergiorgio

  • I

    Igai, Hitoshi

  • S

    Saito, Yuichi

  • T

    Tsoukalas, Nikolaos

  • N

    Nakada, Takeo

  • L

    Li, Shiyue (通讯)

    1 · guangzhou med univ

  • C

    Chen, Rongchang (通讯)

    1 · guangzhou med univ · 2

登录解锁更多功能

  • 收藏这篇,随时在“我的 · 收藏”找回
  • 认领你的成果,生成推广素材
  • 关注作者获取最新成果
  • 加入项目组、协同写作
注册 / 登录

产品服务

  • 科研之友
  • 创新城
  • 科创云

服务支持

  • 帮助中心
  • 隐私政策
  • 服务条款

联系方式

在线客服:【】
客服热线:400-1616-289
电子邮箱:support@scholarmate.com

关注或下载科研之友

微信二维码
微信公众号
客户端下载二维码
下载客户端
科研成果科研人员科研机构科研动态爱瑞思软件

©2026 深圳市科研之友网络服务有限公司

公安备案图标粤公网安备 44030502000213
粤ICP备 16046710 号粤B2-20110417